- Home
- KNOP vs CHRS Comparison
KNOP vs CHRS Comparison
Compare KNOP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- CHRS
- Stock Information
- Founded
- KNOP 2013
- CHRS 2010
- Country
- KNOP United Kingdom
- CHRS United States
- Employees
- KNOP N/A
- CHRS N/A
- Industry
- KNOP Marine Transportation
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KNOP Consumer Discretionary
- CHRS Health Care
- Exchange
- KNOP Nasdaq
- CHRS Nasdaq
- Market Cap
- KNOP 187.6M
- CHRS 191.3M
- IPO Year
- KNOP 2013
- CHRS 2014
- Fundamental
- Price
- KNOP $5.76
- CHRS $1.24
- Analyst Decision
- KNOP
- CHRS Strong Buy
- Analyst Count
- KNOP 0
- CHRS 4
- Target Price
- KNOP N/A
- CHRS $5.38
- AVG Volume (30 Days)
- KNOP 89.3K
- CHRS 2.0M
- Earning Date
- KNOP 02-24-2025
- CHRS 03-12-2025
- Dividend Yield
- KNOP 1.81%
- CHRS N/A
- EPS Growth
- KNOP N/A
- CHRS N/A
- EPS
- KNOP N/A
- CHRS N/A
- Revenue
- KNOP $299,790,000.00
- CHRS $304,340,000.00
- Revenue This Year
- KNOP $7.66
- CHRS $2.47
- Revenue Next Year
- KNOP $1.75
- CHRS N/A
- P/E Ratio
- KNOP N/A
- CHRS N/A
- Revenue Growth
- KNOP 4.75
- CHRS 44.19
- 52 Week Low
- KNOP $4.94
- CHRS $0.66
- 52 Week High
- KNOP $9.11
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- KNOP 45.64
- CHRS 37.51
- Support Level
- KNOP $5.87
- CHRS $1.38
- Resistance Level
- KNOP $6.14
- CHRS $1.45
- Average True Range (ATR)
- KNOP 0.23
- CHRS 0.13
- MACD
- KNOP -0.02
- CHRS -0.04
- Stochastic Oscillator
- KNOP 12.14
- CHRS 4.50
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.